PARPi focus the spotlight on replication fork protection in cancer

Katharina Schlacher

doi:10.1038/ncb3638

PARPi focus the spotlight on replication fork protection in cancer

Katharina Schlacher

Cancer Biology

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.

Original language	English (US)
Pages (from-to)	1309-1310
Number of pages	2
Journal	Nature cell biology
Volume	19
Issue number	11
DOIs	https://doi.org/10.1038/ncb3638
State	Published - Nov 1 2017

ASJC Scopus subject areas

Cell Biology

Access to Document

10.1038/ncb3638

Cite this

@article{a9bb41d793e9486f95d358fffd064d67,

title = "PARPi focus the spotlight on replication fork protection in cancer",

abstract = "PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.",

author = "Katharina Schlacher",

year = "2017",

month = nov,

day = "1",

doi = "10.1038/ncb3638",

language = "English (US)",

volume = "19",

pages = "1309--1310",

journal = "Nature cell biology",

issn = "1465-7392",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - PARPi focus the spotlight on replication fork protection in cancer

AU - Schlacher, Katharina

PY - 2017/11/1

Y1 - 2017/11/1

N2 - PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.

AB - PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2 downregulation is found to restore DNA replication fork protection but not repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This challenges the DNA repair dominance in synthetic lethality.

UR - http://www.scopus.com/inward/record.url?scp=85032642209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032642209&partnerID=8YFLogxK

U2 - 10.1038/ncb3638

DO - 10.1038/ncb3638

M3 - Review article

C2 - 29087384

AN - SCOPUS:85032642209

SN - 1465-7392

VL - 19

SP - 1309

EP - 1310

JO - Nature cell biology

JF - Nature cell biology

IS - 11

ER -

PARPi focus the spotlight on replication fork protection in cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this